ARTHUR VALL-SPINOSA, M.D.; T. WILLIAM LESTER, M.D.
The available evidence shows that a new drug, rifampin, rivals isoniazid in effectiveness against infection with Mycobacterium tuberculosis. The toxicity of rifampin and the best way to use it have not yet been established. Pending the results of controlled trials now under way, rifampin should be reserved for retreatment chemotherapy and for cases where drug intolerance prevents the use of current standard regimens.
VALL-SPINOSA A, LESTER TW. Rifampin: Characteristics and Role in the Chemotherapy of Tuberculosis. Ann Intern Med. ;74:758–760. doi: 10.7326/0003-4819-74-5-758
Download citation file:
Published: Ann Intern Med. 1971;74(5):758-760.
Infectious Disease, Mycobacterial Infections.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use